SWOG clinical trial number
SWOG-9008 (INT-0116) (RTOG-9018) (NCCTG-90-41-51) (ECOG-6290) (CALGB-9195)

Trial of Adjuvant Chemoradiation After Gastric Resection For Adenocarcinoma, Phase III

Closed
Phase
III
Accrual
100%
Published
Abbreviated Title
Trial of Adjuvant Chemoradiation After Gastric Resection For Adenocarcinoma, Phase III
Activated
08/01/1991
Closed
07/15/1998

Research committees

Gastrointestinal Cancer

Treatment

Surgery

Publication Information Expand/Collapse

2018

Survival by Hispanic Ethnicity among Cancer Patients Participating in SWOG Clinical Trials

M Chavez-MacGregor;J Unger;A Moseley;S Ramsey;DL Hershman Cancer Apr 15;124(8):1760-1769; Jan 25 [Epub ahead of print]

PMid: PMID29370458 | PMC number: PMC5963502

Survival by Hispanic Ethnicity Among Cancer Patients participating in SWOG Clinical Trials

A Moseley;M Chavez-MacGregor;J Unger;S Ramsey;D Hershman Society for Clinical Trials Annual Meeting (May 20-23 2018, Portland, OR), oral presentation

2017

The effect of positive SWOG treatment trials on survival of patients with cancer in the US population

JM Unger;M Leblanc;CD Blanke JAMA Oncology Oct 1;3(10):1345-1351

PMid: PMID28586789; PMC5710507

The impact of positive SWOG treatment trials on population survival

J Unger;M LeBlanc;C Blanke J Clin Oncol 35, 2017 (suppl; abstr 6513); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster discussion

2014

Comparison of survival outcomes among cancer patients treated in and out of clinical trials

J Unger;W Barlow;DP Martin;S Ramsey;M Leblanc;R Etzioni;D Hershman Journal of the National Cancer Institute 106(3):dju002; 2014 Mar 13 [Epub ahead of print];

PMid: PMID24627276 | PMC number: PMC3982777

2013

Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial

MA Gordon;H Gundacker;JS Macdonald;J Baranda;W Levin;C Fenoglio-Preiser;N Wick;CD Blanke;J Benedetti;W Elatre;P Weng;H Lenz;M Press Annals of Oncology 24(7):1754-1761;

PMid: PMID23524864 | PMC number: PMC3690906

Modeling the relationship between progression-free survival and overall survival: the phase 2/3 trial

M Redman;B Goldman;M LeBlanc;A Schott;LH Baker Clinical Cancer Research, 19(10):2646-2656;

PMid: PMID23669424 | PMC number: PMC4131693

2012

Updated analysis of SWOG-directed Intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation following curative gastric resection (CALGB-9195; ECOG-6290; NCCTG-90-41; RTOG 9018 and SWOG-9008

S Smalley;J Benedetti;C Blanke;D Haller;S Hundahl;N Estes;JA Ajani;LL Gunderson;B Goldman;JA Martenson;JM Jessup;GN Stemmerman;JS Macdonald Journal of Clinical Oncology 30(19):2327-2333

PMid: PMID2258569 | PMC number: PMC4517071

Assessment of HER2 Gene Amplification in Adenocarcinomas of the Stomach or Gastroesophageal Junction in the INT-0116/SWOG9008 Clinical Trial

MA Gordon;H Gundacker;J Benedetti;J Macdonald;J Baranda;W Levin;N Wick;C Blanke;W Elatre;P Weng;J-Y Zhou;H Lenz;M Press J Clin Oncol 30 (suppl; abstr 4010); American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), poster discussion;

2011

Gastric Cancer: Nagoya is not New York [PMID22010021]

J Macdonald Journal of Clinical Oncology 29(33):4348-4350

2009

Chemoradiation of resected gastric cancer: a 10 year followup of INT0116 (SWOG 9008)

J Macdonald;J Benedetti;SR Smalley;D Haller;S Hundahl;J Jessup;J Ajani;LL Gunderson;B Goldman;JA Martenson Journal of Clinical Oncology 27:15s, abst. #4515

Report from the Radiation Therapy Committee of the Southwest Oncology Group (SWOG): research objectives workshop 2008 [PMID19723641; PMC2978526]

P Okunieff;LA Kachnic;LS Constine;CD Fuller;LE Gaspar;DF Hayes;J Hooks;C Ling;FL Meyskens;PA Philip;D Raben;SR Smalley;GP Swanson;BA Teicher;CR Thomas;B Vikram;MJ Zelefsky;LH Baker Clinical Cancer Research 15(18):5663-5770

2008

The Southwest Oncology Group: progress in cancer research [PMID18929152]

CA Coltman Seminars in Oncology 35(5):545-552

2007

Improved regional control and survival with "low maruyama index" surgery in gastric cancer: autopsy findings from the Dutch D1-D2 trial [PMID17336241]

SA Hundahl;KCJM Peeters;EK Kranenbarg;H Hartgrink;CJH van de Velde Gastric Cancer 10(2):84-86

Gastric cancer: D2 dissection or low maruyama index-based surgery - a debate [PMID17336241]

HO Douglass;SA Hundahl;JS Macdonald;VP Khatri Surgical Oncology Clinics of North America 16(1):133-155

2006

Low maruyama index surgery for gastric cancer [PMID17577616]

SA Hundahl Scandinavian Journal of Surgery 95(4):243-248

2005

Evidence-based recommendations for local-regional control of gastric cancer

SA Hundahl Cancer Investigation 23(4):352-362

Chapter 45 - Stomach

SA Hundahl;JS Macdonald;SR Smalley In: Chang AE, Ganz PA, Hayes DF, et al. (eds). Oncology: An Evidence Based Approach, New York: Springer-Verlag, pgs 680-703

Changing gastric cancer treatment in the United States and the pursuit of quality

SA Hundahl;HJ Wanebo European Journal of Surgical Oncology 31(6):605-615

Low maruyama index surgery for gastric cancer: blinded re-analysis of the Dutch D1-D2 trial

KCMJ Peeters;SA Hundahl;EK Kranenbarg;H Hartgrink;CJH van de Velde World Journal of Surgery 29:1576-1584

2004

Postoperative combined radiation and chemotherapy improves disease-free survival (DFS) and overall sirvival (OS) in resected adenocarcinoma of the stomach and gastroesophageal junction: update o fthe results of Intergroup study INT-0116 (SWOG 9008)

JS Macdonald;S Smalley;J Benedetti;N Estes;DG Haller;JA Ajani;LL Gunderson;M Jessup;JA Martenson American Society of Clinical Oncology GastrointestinaI Cancers Symposium #6

Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis PMID:15067027

LL Gunderson;DJ Sargent;TE Tepper;N Wolmark;MJ O'Connell;M Begovic;C Allmer;L Colangelo;SR Smalley;DG Haller;JA Martenson;RJ Mayer;TA Rich;JA Ajani;JS MacDonald;CG Willett;RM Goldberg Journal of Clinical Oncology 22(10):1773-1775

Intergroup 0144: A phase III rectal surgical adjuvant study of pelvic radiation (XRT) plus 5-FU based chemotherapy (bolus 5-FU before and after PVI + XRT vs PVI before, during, and after XRT vs biochemically modulated bolus 5-FU and XRT): mature outcome results and pelvic failure analysis

S Smalley;J Benedetti;S Williamson;J Robertson;B Fisher;J Martenson;A Benson;R Mayer;C Cripps;N Estes;J Macdonald Proceedings of American Society for Therapeutic Radiology and Oncology, p. S137, abst. #14

2003

Frequent alterations of B-catenin gene in gastric cancers with microsatellite instability

J Wang;T Shepherd;A Lowy;A Noffsinger;G Stemmermann;C Fenoglio-Preiser Proc of the American Association for Cancer Research 44(2nd.ed): #1199

Report from the Radiation Oncology Committee of the Southwest Oncology Group (SWOG): Research Objectives Workshop 2003 PMID14528084

P Okunieff;RE Meyn;BA Teicher;CR Thomas, Jr.;LE Gaspar;D Raben;S Giri;RS Lavey;AT Turrisi;GP Swanson;SR Smalley American Journal of Clinical Oncology 26(5):522-529

PMid: PMID14528084

2002

B-Catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer

WM Clements;J Wang;A Sarnaik;OJ Kim;JS Macdonald;C Fenoglio-Preiser;J Groden;AM Lowy Cancer Research 62:3503-3506

B-Catenin nuclear staining and mutation in gastric cancer

OJ Kim;J Wang;WM Clements;AA Sarnaik;G Stemmermann;A Noffsinger;G DeVoe;AM Lowy;C Fenoglio-Preiser Modern Pathology 15(1):132a(#551)

Beta-catenin is commonly mutated in human gastric cancers with cyclin D overexpression.

J Wang;ONJ Kim;WM Clements;AA Sarnaik;B Liu;A Noffsinger;G Stemmermann;AM Lowy;CM Fenoglio-Preisor Proc of the American Association for Cancer Research 93:90(#526)

Mutation of the B-catenin gene is a frequent cause of Wnt pathway activation in gastric cancer.

WM Clements;J Wang;A Sarnaik;OJ Kim;JL Groden;C Fenoglio-Preiser;AM Lowy Proc of the American Association for Cancer Research 93:111(#770)

Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatment.

SA Hundahl;JS Macdonald;J Benedetti;T Fitzsimmons Annals of Surgical Oncology 9(3):278-286

Surgical quality in trials of adjuvant cancer therapy

SA Hundahl Journal of Surgical Oncology 80:177-180

2001

Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.

JS Macdonald;SR Smalley;J Benedetti;SA Hundahl;NC Estes;GN Stemmermann;DG Haller;JA Ajani;LL Gunderson;JM Jessup;JA Martenson New England Journal of Medicine 345(10):725-730

E-Cadherin, a and b-catenins in gastric cancer expression

OJ Kim;G Stemmermann;G DeVoe;A Noffsinger;J Macdonald;C Fenoglio-Preiser Modern Pathology 14:88A(#506)

Gastric Cancer

JS Macdonald Clinical Oncology Updates 4(3):1-7

2000

Alterations in exon 4 of the p53 gene in gastric carcinoma

T Shepherd;D Tolbert;J Benedetti;J Macdonald;G Stemmerman;J Wiest;G DeVoe;MA Miller;J Wang;A Noffsinger;C Fenoglio-Preiser Gastroenterology 118:1039-1044

Postoperative combined radiation and chemotherapy improves disease-free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and G.E. junction. results of Intergroup study INT-0116 (SWOG 9008)

JS Macdonald;S Smalley;J Benedetti;N Estes;DG Haller;JA Ajani;LL Gunderson;M Jessup;JA Martenson Proc of the American Society of Clinical Oncology 19:1a(#1)

Intergroup 0116 (SWOG 9008)- Phase III trial of postoperative adjuvant radiochemotherapy for high risk gastric and gastroesophageal (GE) junction adenocarcinoma (ACA): evaluation of efficacy and radiotherapy treatment planning

S Smalley;J Benedetti;L Gunderson;J Martenson;J Tepper;K Kiel;A Lichter;J Forman;J Macdonald Int J Radiat Oncol Biol Phys 48(3)Suppl:111-112

Thioredoxin, a putative oncogene product is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival

TM Grogan;C Fenoglio-Prieser;R Zeheb;W Bellamy;Y Frutiger;E Vela;G Stemmerman;J Macdonald;L Richter;A Gallegos;G Powis Human Pathology 31(4):475-481

A simple classification of gastric cancer

OJ Kim;G Stemmermann;A Noffsinger;C Fenoglio-Preiser Modern Pathology 13(1):83a(#474)

1999

p53 immunoreactivity and single-strand conformational polymorphism analysis often fail to predict p53 mutational status.

DM Tolbert;AE Noffsinger;MA Miller;GW DeVoe;GN Stemmermann;JS Macdonald;CM Fenoglio-Preiser Modern Pathology 12(1):54-60

The relation of p53 gene mutations to gastric cancer subsite and phenotype.

D Tolbert;C Fenoglio-Preiser;A Noffsinger;G De Voe;J Macdonald;J Benedetti;GM Stemmermann Cancer Causes and Control 10:227-231

Alterations in exon 4 of the p53 gene in gastric cancer.

D Tolbert;AE Noffsinger;GN Stemmermann;CM Fenoglio-Preiser Proc of the American Association for Cancer Research 40:346(#2289)

Minisatellite instability in gastric cancer

YE Nikiforov;T Schulte;GN Stemmermann;AN Noffsinger;CM Fenoglio-Preiser Laboratory Investigation 79:81A(#463)

1998

Inadequate documentation and resection for gastric cancer in the United States: A preliminary report.

NC Estes;JS Macdonald;K Touijer;J Benedetti;J Jacobson The American Surgeon 64(7):680-685

1997

Detection of microsatellite instability and p53 gene mutations in advanced gastric carcinomas.

D Tolbert;A Noffsinger;G Stemmermann;C Fenoglio-Preiser International Academy of Pathology Book of Abstracts :65A(#369)

1996

Immunohistochemical analysis of bcl-2 family proteins in adenocarcinomas of the stomach.

M Krajewska;CM Fenoglio-Preiser;JS Macdonald;G Stemmerman;JC Reed American Journal of Pathology 149(5):1449-1457

Pathologic and phenotypic features of gastric cancer.

CM Fenoglio-Preiser;AE Noffsinger;J Belli;GN Stemmermann Seminars in Oncology 23(3):292-306

Other Clinical Trials

SWOG Clinical Trial Number
S9304A-ICSC

Investigation of Thioredoxin-1 Family Protein Expression in Rectal Cancer

Research Committee(s)
Gastrointestinal Cancer
Closed
SWOG Clinical Trial Number
SWOG-8037

Combined Therapies for Squamous Cell Carcinoma of the Esophagus

Research Committee(s)
Gastrointestinal Cancer
Activated
02/16/1981
Closed
01/19/1984
Closed
Phase
II
Published
SWOG Clinical Trial Number
SWOG-8591(NCI Intergroup #0035)

An Evaluation of Levamisole Alone or Levamisole plus 5-Fluorouracil as Surgical Adjuvant Treatment for Resectable Adenocarcinoma of the Colon

Research Committee(s)
Gastrointestinal Cancer
Activated
01/14/1985
Closed
10/01/1987
Closed
Phase
Published